APOE and Alzheimer disease: Generally, using risk factors of AD related to cognitive decline, such as biomarkers of amyloid beta 42 (Aβ42), phosphorylated Tau (pTau), and apolipoprotein E (ApoE) ε4, as a stratification index in randomization can reduce the allocation biases in cognitive decline.